(Total Views: 207)
Posted On: 09/11/2019 4:25:47 PM
Post# of 231
NetworkNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) TUSC2 Found to Prevent Tumor Growth in Triple-Negative Breast Cancer by Independent Researchers
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that non-affiliated, independent researchers have reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, prevented tumor growth in triple-negative breast cancer (“TNBC”). Currently considered an incurable cancer, there are limited therapeutic options available for TNBC. “The results of the study evaluating TUSC2 for the treatment of triple-negative breast cancer are encouraging,” Genprex Chairman and CEO Rodney Varner said in the news release. “We believe that the data reported in this Nature article by independent researchers supports our belief that TUSC2 may be effective to treat a variety of cancers, including some of the most deadly types of cancer.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that non-affiliated, independent researchers have reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, prevented tumor growth in triple-negative breast cancer (“TNBC”). Currently considered an incurable cancer, there are limited therapeutic options available for TNBC. “The results of the study evaluating TUSC2 for the treatment of triple-negative breast cancer are encouraging,” Genprex Chairman and CEO Rodney Varner said in the news release. “We believe that the data reported in this Nature article by independent researchers supports our belief that TUSC2 may be effective to treat a variety of cancers, including some of the most deadly types of cancer.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
